Pfizer Inc. (PFE) earnings on August 4, 2026

Before the market opens Q2 2026

More Pfizer Inc. earnings

Prior outlook: Optimistic Outcome: Accurate

Pfizer's stock swung widely during the day, dropping 1.3% and climbing 2.4% before closing 1.5% higher. Some investors sold after a recent rise, despite the company's strong track record and positive news from health regulators.

PFE price around the earnings

25.41

Change: +1.5%

2026-08-04, 20:00 UTC

Start of the measured window End of the measured window
24.77 25.06 25.35 25.64 25.03
Price series around the eventClosing price per minute from before the event to the end of the measured window.
August 4, 2026
  • Price: green if it ends above the starting price; red if it ends below
  • Start of the measured window
  • End of the measured window
  • Market open
  • Starting price
Price series around the event

Prior thesis

Prior outlook: Optimistic Outcome: Accurate

Thesis published
Results released

Strong expectations, scenario optimistic

Experts are optimistic: the company has a strong recent record of beating earnings forecasts, analysts point to an optimistic scenario, and positive news about drugs and vaccines is boosting sentiment.

Context analyzed before publication

Summary
Strong expectations, scenario optimistic
Playbook
The stock has been rising recently, and analysts cite about 15% upside to their price target. Positive news flow and high retail interest are supporting the trend.
Trend
Expert outlook improved steadily over the week

Analysts

Drivers

  • Analysts Positive

    Analysts cite a price target about 15% above the current price, with a consensus 'buy' rating from 26 analysts and expected earnings growth.

Evidence

Analyst consensus
Buy
Consensus average (1-5)
2.46
Analysts covering the stock
26
Average price target
28.75
Lowest price target
24
Highest price target
35.46
Upside to price target
14.9%
Quarterly earnings growth
-9.4%
Revenue growth
5.4%
Forward EPS
2.83
Trailing EPS
1.31
Analyst moves in the last 60 days
7
  • Strong buy: 2
  • Buy: 8
  • Hold: 16
  • Sell: 1
  • Strong sell: 1
Strong buy
2
Buy
8
Hold
16
Sell
1
Strong sell
1
  • July 13, 2026 · BMO Capital: Maintains rating (Outperform → Outperform)
  • July 13, 2026 · Guggenheim: Maintains rating (Buy → Buy)
  • July 10, 2026 · B of A Securities: Maintains rating (Neutral → Neutral)
  • July 8, 2026 · JP Morgan: Maintains rating (Neutral → Neutral)
  • July 6, 2026 · Cantor Fitzgerald: Reiterates rating (Neutral → Neutral)
  • July 6, 2026 · HSBC: Downgrades rating (Buy → Hold)
  • June 10, 2026 · RBC Capital: Upgrades rating (Underperform → Sector Perform)

News and sentiment

Drivers

  • News & sentiment Positive

    Positive news about drug trials and vaccines is providing a boost, and retail sentiment is very positive with high market review volume.

Evidence

Sentiment
Sentiment
Constructive
Mention volume
High
Normalized volume
99%
News
Sources (8)

Technicals

Evidence

Price when the context was analyzed
25.05
Average true range (ATR)
2%
Distance to 52-week high
-9.4%
14-day change (14d)
+1.2%
30-day change (32d)
+3.0%
30-day relative strength
+1.3%
SPY change (32d)
+1.7%
Nearest support
24.97
Distance to nearest support
0.3%
Nearest resistance
25.13
Distance to nearest resistance
0.3%
Volume accumulation ratio (14d / 46d)
0.98
  • Major: 24.97 (0.3% away, 0.15 ATR, 39 touches)
  • Mid: 24.89 (0.6% away, 0.31 ATR, 13 touches)
  • Major: 24.76 (1.1% away, 0.56 ATR, 33 touches)
  • Major: 25.13 (0.3% away, 0.16 ATR, 54 touches)
  • Major: 25.21 (0.6% away, 0.32 ATR, 46 touches)
  • Major: 25.36 (1.3% away, 0.63 ATR, 42 touches)

Trends

Evidence

Average earnings surprise
+23.4%
  • May 5, 2026: actual EPS 0.75 vs estimate 0.72 (surprise +3.9%)
  • February 3, 2026: actual EPS 0.66 vs estimate 0.57 (surprise +16.2%)
  • November 4, 2025: actual EPS 0.87 vs estimate 0.63 (surprise +37.4%)
  • August 5, 2025: actual EPS 0.78 vs estimate 0.57 (surprise +35.9%)

Expected move

Drivers

  • Past earnings Positive

    The company has beaten earnings forecasts in all recent quarters, with an average surprise of +23.4%, the strongest in its group.

Implied move
+2.3%
Source
Options chain

Reactions over its last 20 earnings

Median move
2%
75th percentile move
3.2%
90th percentile move
4.2%
Up / down moves
10 / 10
Average up move
+3.1%
Average down move
-1.6%

Monitoring and close

What Pfizer Inc. reported

Status
Finished
Actual EPS0.77
EPS estimate0.69
EPS surprise+11.6%
Revenue$15,034 million
Revenue estimate$14,412 million
Revenue surprise+4.3%

Pfizer beat expectations and raised 2026 guidance, driven by Eliquis. A monthly GLP-1 candidate could rival tirzepatide. Overall outlook remains optimistic.

Sources (28)

Pre-market second reading after the results

Verdict
Beat expectations

Heading into the open, results beat expectations on both earnings and revenue, and the price is indicating +0.4% pre-market, a move below the stock's usual reaction (about 2%). The figures don't confirm the prior scenario: that move is too small to draw conclusions from.

How the stock reacted

Outcome
Accurate
Consolidated
+1.5%
Max favorable move (MFE)
2.4%
Max adverse move (MAE)
1.3%